Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

69 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Venetoclax consolidation after fixed-duration venetoclax plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (HOVON 139/GiVe): primary endpoint analysis of a multicentre, open-label, randomised, parallel-group, phase 2 trial.
Kersting S, Dubois J, Nasserinejad K, Dobber JA, Mellink C, van der Kevie-Kersemaekers AF, Evers LM, de Boer F, Koene HR, Schreurs J, van der Klift M, Velders GA, van der Spek E, van der Straaten HM, Hoogendoorn M, van Gelder M, Posthuma EFM, Visser HPJ, Houtenbos I, Idink CAM, Issa DE, Dompeling EC, van Zaanen HCT, Veelken H, Levenga H, Tick LW, Terpstra WE, Tonino SH, Boyer M, Mobasher M, Levin MD, Kater AP; HOVON CLL study group. Kersting S, et al. Among authors: posthuma efm. Lancet Haematol. 2022 Mar;9(3):e190-e199. doi: 10.1016/S2352-3026(22)00034-5. Lancet Haematol. 2022. PMID: 35240075 Clinical Trial.
Real-world costs of chronic lymphocytic leukaemia in the Netherlands.
Holtzer-Goor KM, Bouwmans-Frijters CA, Schaafsma MR, de Weerdt O, Joosten P, Posthuma EF, Wittebol S, Huijgens PC, Mattijssen EJ, Vreugdenhil G, Visser H, Peters WG, Erjavec Z, Wijermans PW, Daenen SM, van der Hem KG, van Oers MH, Groot CA. Holtzer-Goor KM, et al. Leuk Res. 2014 Jan;38(1):84-90. doi: 10.1016/j.leukres.2013.10.029. Epub 2013 Nov 8. Leuk Res. 2014. PMID: 24268350
Quality of life of patients with chronic lymphocytic leukaemia in the Netherlands: results of a longitudinal multicentre study.
Holtzer-Goor KM, Schaafsma MR, Joosten P, Posthuma EF, Wittebol S, Huijgens PC, Mattijssen EJ, Vreugdenhil G, Visser H, Peters WG, Erjavec Z, Wijermans PW, Daenen SM, van der Hem KG, van Oers MH, Uyl-de Groot CA. Holtzer-Goor KM, et al. Qual Life Res. 2015 Dec;24(12):2895-906. doi: 10.1007/s11136-015-1039-y. Epub 2015 Jul 24. Qual Life Res. 2015. PMID: 26205768 Free PMC article.
Treatment strategies for polycythemia vera: Observations in a Dutch "real-world" cohort study.
van de Ree-Pellikaan C, de Kreuk A, Schaar CG, Beeker A, Dompeling EC, Gerrits CJH, van Houten AA, Schipperus MR, Strobbe L, Posthuma EFM, Klauke K, Westerweel PE. van de Ree-Pellikaan C, et al. Among authors: posthuma efm. Eur J Haematol. 2019 Nov;103(5):453-459. doi: 10.1111/ejh.13291. Epub 2019 Sep 5. Eur J Haematol. 2019. PMID: 31298768 Clinical Trial.
Survival continues to increase in chronic lymphocytic leukaemia: a population-based analysis among 20 468 patients diagnosed in the Netherlands between 1989 and 2016.
van der Straten L, Levin MD, Visser O, Posthuma EFM, Doorduijn JK, Kater AP, Dinmohamed AG. van der Straten L, et al. Among authors: posthuma efm. Br J Haematol. 2020 May;189(3):574-577. doi: 10.1111/bjh.16397. Epub 2020 Jan 20. Br J Haematol. 2020. PMID: 31958141 Free article. No abstract available.
Possible hampered effectiveness of second-line treatment with rituximab-containing chemotherapy without signs of rituximab resistance: a population-based study among patients with chronic lymphocytic leukemia.
van der Straten L, Kater AP, Doorduijn JK, van den Broek EC, Posthuma EFM, Dinmohamed AG, Levin MD. van der Straten L, et al. Among authors: posthuma efm. Ann Hematol. 2020 May;99(5):1081-1091. doi: 10.1007/s00277-020-03994-8. Epub 2020 Mar 19. Ann Hematol. 2020. PMID: 32193628
69 results